November 8, 2004
BioCell Receives Manufacturing Patent
NEWPORT BEACH, Calif.
BioCellTechnology LLC was awarded U.S. Patent No. 6,780,841 for the manufacturingprocess of its BioCell Collagen II®, hydrolyzed collagen Type II withhyaluronic acid (HA) and chondroitin sulfate. The patent covers themanufacturing process, preparation and use of hydrolyzed collagen Type II powdercompositions administered orally or topically for connective tissue disordersand skin elasticity.
BioCell has worked diligently to provide consumers with thehighest concentrated natural source of collagen Type II available in themarketplace today, said Suhail Ishaq, vice president of BioCell(www.biocelltechnology.com). Our advanced ingredient and manufacturingprocess is supported by credible scientific research. As our third patent, weare confident that it will protect our innovative technology and furthervalidate the quality of BioCell Collagen II and the ingredients efficacy forjoint and skin health benefits.
You May Also Like
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023